- 18
- 2 161
EUCOPE
Приєднався 3 лют 2021
EUCOPE is the trade association giving a bigger voice to small and mid-sized health technology companies in Europe
For more than a decade, the European Confederation of Pharmaceutical Entrepreneurs (EUCOPE) has been the voice of small to mid-sized health technology companies in Europe. As a trade association, we advocate for sound public policy that supports innovation, while fostering a community built on a shared purpose: improving and saving the lives of European patients through innovative therapies and medical technology.
EUCOPE’s members - who represent over 2600+ innovative companies directly or via associations - are researching, designing, developing, supplying, manufacturing, and deploying the next generation of pharmaceutical innovation and therapeutic solutions around the continent.
For more than a decade, the European Confederation of Pharmaceutical Entrepreneurs (EUCOPE) has been the voice of small to mid-sized health technology companies in Europe. As a trade association, we advocate for sound public policy that supports innovation, while fostering a community built on a shared purpose: improving and saving the lives of European patients through innovative therapies and medical technology.
EUCOPE’s members - who represent over 2600+ innovative companies directly or via associations - are researching, designing, developing, supplying, manufacturing, and deploying the next generation of pharmaceutical innovation and therapeutic solutions around the continent.
Life Science Lecture 9 - Preparing for the new EU HTA regulation (JCA JSC)
From 12 January 2025 the EU HTA Regulation will apply and the first Joint Clinical Assessments (JCA) will be performed to assess the relative clinical effectiveness of new innovative cancer therapies and cell and gene therapies approved by the EMA. In just three years, by 13 January 2028, these joint assessments will also be performed for all new Orphan Medicinal Products (OMPs).
Get prepared ! In this one-hour session, EUCOPE experts Alexander Natz and Matias Olsen explain the final procedural rules that have been adopted in 2024 in the various Implementing Acts and walk you through the procedural steps and the practical guidance documents that have been adopted by the HTA Coordination Group. They also answer participants' questions.
Reach out to EUCOPE for further information.
Get prepared ! In this one-hour session, EUCOPE experts Alexander Natz and Matias Olsen explain the final procedural rules that have been adopted in 2024 in the various Implementing Acts and walk you through the procedural steps and the practical guidance documents that have been adopted by the HTA Coordination Group. They also answer participants' questions.
Reach out to EUCOPE for further information.
Переглядів: 119
Відео
EUCOPE #LifeScienceLectures Ep. 8: Implementing the EHDS
Переглядів 5944 місяці тому
On 2 September 2024, EUCOPE held a webinar entitled Implementing the European Health Data Space (EHDS): Your journey from regulation to implementation. The discussion highlighted the critical importance of understanding this new legislation and its impact on the pharmaceutical industry. During the session, our expert speakers delved into the complexities of the EHDS, exploring how it will resha...
EUCOPE #LifeScienceLectures ep. 6: "Making CBHC for ATMPs in Rare Diseases a Reality"
Переглядів 587 місяців тому
EUCOPE hosted the sixth episode of Life Science Lectures on how to make cross-border healthcare (CBHC) for ATMPs reality for people living with a rare disease. Our speakers stressed that CBHC is the only option for many patients, especially those living in smaller Member States. Thus, it is important to harmonise existing legislations to improve how it functions. We need timely leadership from ...
EUCOPE #LifeScienceLectures Ep. 5 "The new EU HTA procedure: How can JCAs support access to OMPs
Переглядів 437 місяців тому
EUCOPE hosted the fifth episode of Life Science Lectures on the new EU HTA procedure, and how JCAs can support access to OMPs for people living with a Rare Disease. Moderated by our Alexander Natz, our speakers stressed the need to be flexible in the methodology for OMPs, taking into account the specificities of rare and ultra-rare diseases. Using adequate information will avoid biased discussi...
EUCOPE's #LifeScienceLectures - Episode Four "Leveraging early advice opportunities in EU HTA"
Переглядів 307Рік тому
On the fourth episode, we discuss how best to navigate early advice opportunities with the new EU health technology assessment (HTA), which will be mandatory for all new oncology products and ATMPs from 12 January 2025.
EUCOPE's #LifeScienceLectures - Episode Three "EU HTA Regulation"
Переглядів 147Рік тому
On the third episode, we will talk about the interactions between the EU Health Technology Assessment (#HTA) Regulation and the Pharmaceutical Package. The (EU) Regulation 2021/2282 on health technology assessment (HTA) and the revision of the #pharmaceutical manufacturing legislation will play a key role in patients’ access to innovative therapies in the coming decades. While the two legal ref...
EUCOPE's #LifeScienceLectures - Episode Two "Defining High Unmet Medical Need (HUMN)"
Переглядів 60Рік тому
EUCOPE's Life Science Lectures - Episode Two "Defining High Unmet Medical Need: Will it steer innovation towards filling existing gaps" 📅7 July 2023 The revised pharmaceutical framework includes a definition of UMN and HUMN, which aims at steering innovation toward therapeutic areas with existing gaps, especially in #rarediseases. For the second episode in our Life Science Lectures #webinar ser...
EUCOPE's Life Science Lectures - Episode One "Attaching Conditionalities to Incentives"
Переглядів 70Рік тому
On 30 May, EUCOPE - the European Confederation of Pharmaceutical Entrepreneurs hosted the inaugural episode of the Life Science Lectures webinar series titled “Attaching conditionalities to incentives: the right path to improve access?” Episode One delved into the incentive system outlined in the EU Pharmaceutical Package, with the aim to shed light on how these provisions could impact innovati...
WEBINAR: How recent legislative changes impact the German P&R landscape
Переглядів 296Рік тому
The statutory health insurance financial stabilization act, approved by German Parliament last November, made substantial changes to the characteristics of pricing and reimbursement in Europe’s largest pharmaceutical market. For instance, the new law reduces the free pricing period from 12 to 6 months and changes the guard rails of the additional benefit assessment determining price anchors for...
EUCOPE Partnerships in Focus - Sheela Upadhyaya, FIPRA / Together4RareDiseases
Переглядів 352 роки тому
At EUCOPE, our commitment is to lead and engage in #partnerships spanning the entire medicine lifecycle to find actionable solutions that benefit our members, the patients they serve, and #healthcare systems overall. Our Partnerships in Focus series highlights different associates that we partner with to co-create solutions to various challenges across the healthcare ecosystem related to #healt...
Webinar: "The Future of Rare Diseases in Europe & Czech Republic"
Переглядів 692 роки тому
This special webinar gives an insight into the ways the #European framework on #rarediseases paves the way forward and complements actions at the national level. We hold this debate with representatives of the #CzechRepublic that will hold the rotating presidency of the Council from July 2022 to December 2022. 🔑The event focuses on how the debate regarding fostering innovation and patient acces...
EUCOPE Partnerships in Focus - Maciej Gajewski, Alexion-AstraZeneca
Переглядів 482 роки тому
At EUCOPE, our commitment is to lead and engage in #partnerships spanning the entire medicine lifecycle to find actionable solutions that benefit our members, the patients they serve and #healthcare systems overall. Our Partnerships in Focus series highlights different associates that we partner with to co-create solutions to various challenges across the healthcare ecosystem related to #health...
EUCOPE Partnerships in Focus - Toon Digneffe, Takeda
Переглядів 512 роки тому
At EUCOPE, our commitment is to lead and engage in partnerships spanning across the entire medicine lifecycle to find actionable solutions that benefit our members, the patients they serve and healthcare systems overall. Our Partnerships in Focus series highlights different associates that we partner with to co-create solutions to various challenges across the #healthcare ecosystem related to h...
Pulling out all the stops to deliver high-quality care for European cancer patients
Переглядів 443 роки тому
Pulling out all the stops to deliver high-quality care for European cancer patients
The Future of Rare Diseases in Sweden & Denmark
Переглядів 903 роки тому
EUCOPE and IML webinar on the impact, challenges and opportunities of the OMP Regulation review for the rare disease community in Denmark and Sweden along with a panel of EU and national stakeholders.
Table ronde: L' avenir des maladies rares
Переглядів 583 роки тому
Table ronde: L' avenir des maladies rares
EUCOPE - BIO Webinar: The EU and US Biotech Sector’s Response to COVID-19
Переглядів 203 роки тому
EUCOPE - BIO Webinar: The EU and US Biotech Sector’s Response to COVID-19
🌷 "Promo sm"